Maveral

Fluvoxamine Maleate, the active ingredient in Maveral, is a selective serotonin reuptake inhibitor presented as an oral tablet for oral use. It is prescribed for major depressive disorder, obsessive‑compulsive disorder, panic disorder and social anxiety in adult patients.

GNH USA supplies Maveral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution.

Fluvoxamine, an SSRI, is used to treat several psychiatric conditions by enhancing serotonergic neurotransmission. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Obsessive‑compulsive disorder: reduces compulsive thoughts and repetitive behaviors. - Panic disorder: decreases frequency and severity of panic attacks. - Social anxiety disorder: lessens social fear and avoidance behaviors.

Fluvoxamine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Headache: transient cranial discomfort. - Dry mouth: reduced salivary flow. - Dizziness: occasional light‑headedness. - Sexual dysfunction: decreased libido or delayed orgasm.

Serious or Rare Side Effects: - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Suicidal ideation: emergent thoughts of self‑harm, especially early in therapy. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety factors. - Dose adjustment: required in hepatic impairment. - Monitor: for emergence of suicidal thoughts, especially early in treatment. - Avoid: concurrent use with monoamine oxidase inhibitors. - Caution: in patients with renal dysfunction. - Pregnancy: risk unknown; weigh benefits versus potential fetal risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Fluvoxamine interacts with several drug classes; some combinations must be avoided while others require close monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Thioridazine: can cause QT prolongation and cardiac arrhythmias. - Tramadol: increased risk of seizures and serotonin toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: fluvoxamine may enhance anticoagulant effect; monitor INR. - Carbamazepine: may reduce fluvoxamine plasma levels; adjust dose if needed. - Benzodiazepines: may increase sedation; observe patient response.